Chávez-Ortiz Zaide G, López-Valladares KE, Benavides-Badillo MA, Parra-Ortega I, López-Martínez B

Language: Spanish
References: 10
Page: 159-162
PDF size: 310.02 Kb.

ABSTRACT

Introduction: Autoimmunity is an anomaly in the immune response to its own antigens due to the loss of tolerance and the generation of autoantibodies. Objectives: To evaluate the usefulness of the detection of these markers in the diagnosis of autoimmune diseases especially SAAF in pediatric patients of the Hospital Infantil de México Federico Gómez. To determine the prevalence of antiphospholipid antibody isotypes. Material and methods: From January 1, 2015 to June 30, 2017, 336 trials were obtained for the determination of lupus anticoagulant (AL) by the method of diluted Russell’s viper venom, anticardiolipin antibody (aCL) and anti-β2GPI (aβ2GPI) by ELISA. Results: 54% of the trials were negative and 46% positive for one or more markers. Within the positives 58% was positive only for AL and 42% for AL + aCL and / or aβ2GPI, with the aβ2GPI IgM isotype being the most prevalent. Of those who were positive, 62% were used to integrate a diagnosis for Autoimmune Diseases, the most frequent being systemic lupus erythematosus (35%) and SAAF (21%). Only the aCL and aβ2GPI markers were statistically significant in the study. Conclusions: The diagnosis of autoimmune diseases turns out to be complicated due to the fact that a large number of autoantigenic determinants are generated that may have some of these determinants in common, so that the need arises to find analytical methods that have high sensitivity and specificity, in this study only aCL and aβ2GPI are statistically significant markers.

REFERENCES

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4 (2): 295-306.

2. Espinosa G, Cervera R. Antiphospholipid syndrome. Arthritis Rheum 2008 (64): 1-10

3. Lirola MJ, Camacho MS. Síndrome antifosfolípido pediátrico. Protoc Diagn Ter Pediatr. 2014; 1: 79-89.

4. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009; 7 (10): 1737-1740.

5. Lakos G, Favaloro EJ, Harris EN, Meroni PL, Tincani A, Wong RC et al. International consensus guidelines on anticardiolipin and anti-β2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum. 2012; 64 (1): 1-10.

6. Alfaro-Pacheco R. Síndrome antifosfolípido. Rev Med de Costa Rica y Centro América. 2009; 66 (58): 313-317.

7. Tincani A, Allegri F, Balestrieri G, Reber G, Sanmarco M, Meroni P et al. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb Res. 2004; 114 (5-6): 553-558.

8. Amengual O, Atsumi T, Khamashta MA, Koike T, Hughes GR. Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol. 1996; 35 (12): 1239-1243.

9. Wong RC, Favaloro EJ. Clinical features, diagnosis, and management of the antiphospholipid syndrome. Semin Thromb Hemost. 2008; 34 (3): 295-304.

10. Marai I, Gilburd B, Blank M, Shoenfeld Y. Anti-cardiolipin and anti-beta2-glycoprotein I (beta2GP-I) antibody assays as screening for anti-phospholipid syndrome. Hum Antibodies. 2003; 12 (3): 57-62.